maklogo
Market Research Report

Global Liposomal Amphotericin B Market Insights, Size, and Forecast By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes), By Indication (Invasive Fungal Infections, Cryptococcal Meningitis, Aspergillosis, Candidiasis, Visceral Leishmaniasis, Others), By Dosage Strength (2 mg/vial, 10 mg/vial, 50 mg/vial), By Form (Lyophilized Powder for Injection, Lipid Suspension), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:71775
Published Date:Mar 2026
No. of Pages:210
Base Year for Estimate:2025
Format:
Customize Report

Global Liposomal Amphotericin B Market

Key Market Insights

Global Liposomal Amphotericin B Market is projected to grow from USD 1.25 Billion in 2025 to USD 2.41 Billion by 2035, reflecting a compound annual growth rate of 8.2% from 2026 through 2035. This market encompasses the global demand for a sophisticated antifungal medication formulated as liposomes, offering enhanced efficacy, reduced toxicity, and improved patient tolerability compared to conventional amphotericin B. Liposomal amphotericin B is a critical treatment option for severe and life threatening fungal infections, particularly in immunocompromised patients. Key market drivers include the rising incidence of invasive fungal infections, especially among critically ill and immunosuppressed populations such as cancer patients undergoing chemotherapy, organ transplant recipients, and HIV/AIDS patients. The increasing awareness and diagnosis of these infections, coupled with growing healthcare expenditure and improving healthcare infrastructure in developing economies, further propel market expansion. Additionally, the drug's superior safety profile, which reduces the risk of nephrotoxicity and infusion related reactions, makes it a preferred choice over traditional formulations, driving its adoption across various clinical settings.

Global Liposomal Amphotericin B Market Value (USD Billion) Analysis, 2025-2035

maklogo
8.2%
CAGR from
2026-2035
Source:
www.makdatainsights.com

Important trends shaping the market include advancements in liposomal drug delivery systems aimed at further optimizing drug stability, bioavailability, and targeted delivery. The expansion of research and development activities into new indications and combination therapies is also a significant trend. Moreover, the increasing focus on personalized medicine approaches and the development of biosimilars for liposomal amphotericin B are expected to influence market dynamics. However, market restraints include the high cost associated with liposomal formulations, which can limit access in resource constrained settings. Stringent regulatory approval processes and the potential for new antifungal drug discoveries to displace existing treatments also pose challenges. Despite these restraints, significant market opportunities lie in the expansion of indications for liposomal amphotericin B to treat a broader spectrum of fungal infections, particularly those demonstrating resistance to other antifungal agents. Furthermore, the growing prevalence of multidrug resistant fungal pathogens creates an urgent need for effective and well tolerated treatments, providing a fertile ground for market growth.

North America currently dominates the global market, driven by its advanced healthcare infrastructure, high prevalence of immunocompromised patients, robust research and development activities, and favorable reimbursement policies. The presence of key market players and a high adoption rate of premium priced medications also contribute to its leading position. Asia Pacific is identified as the fastest growing region, attributed to improving healthcare access, increasing healthcare expenditure, rising awareness of fungal infections, and the expanding patient pool, particularly in countries like China and India. The leading market segment by dosage strength is 50 mg/vial, reflecting its widespread use as a standard therapeutic dose for various indications. Key players in this competitive landscape include Glenmark Pharmaceuticals Ltd., Gilead Sciences Inc., United Biotech Pvt. Ltd., Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Cipla Limited, Astellas Pharma Inc., Samarth Life Sciences Pvt. Ltd., and Bristol-Myers Squibb Company. These companies are actively engaged in strategic initiatives such as product innovation, geographical expansion, collaborations, and mergers and acquisitions to strengthen their market presence and expand their product portfolios.

Quick Stats

  • Market Size (2025):

    USD 1.25 Billion

  • Projected Market Size (2035):

    USD 2.41 Billion

  • Leading Segment:

    50 mg/vial (82.4% Share)

  • Dominant Region (2025):

    North America (38.2% Share)

  • CAGR (2026-2035):

    8.2%

Global Liposomal Amphotericin B Market Emerging Trends and Insights

Targeted Delivery Innovations Expanding Use Cases

Targeted delivery innovations are significantly broadening the application of liposomal amphotericin B beyond its traditional systemic antifungal use. Advances in designing liposomes with specific ligands and surface modifications enable precise drug accumulation at disease sites. This opens doors for treating localized infections more effectively, minimizing systemic toxicity often associated with conventional amphotericin B. Furthermore, researchers are exploring novel applications in oncology, where targeted liposomal delivery can deliver high drug concentrations to tumors while sparing healthy tissues, improving therapeutic indices for various cancers. Neurological disorders, parasitic diseases, and even inflammatory conditions are emerging as promising new frontiers. These innovations address unmet medical needs by improving efficacy and safety, fostering the drug’s adoption in specialized and previously inaccessible therapeutic areas.

Combination Therapies Driving Market Growth

Combination therapies are significantly fueling growth in the global liposomal amphotericin B market. This trend is driven by the increasing recognition of synergistic effects achieved when liposomal amphotericin B is administered alongside other antifungal agents or non antifungal drugs. Clinicians are adopting these multi drug regimens to enhance treatment efficacy against severe and refractory fungal infections, reduce the duration of therapy, and potentially mitigate the emergence of drug resistance. For example, combining it with azoles or echinocandins allows for broader spectrum coverage and improved outcomes in immunocompromised patients. Additionally, the use of liposomal amphotericin B in conjunction with immunomodulators or other supportive care drugs is demonstrating superior patient responses and reduced toxicity, thereby expanding its applications beyond conventional monotherapy. This strategic bundling of treatments presents a compelling value proposition for healthcare providers, ultimately translating into increased demand and market expansion for liposomal amphotericin B.

Biosimilar Introductions Reshaping Competitive Landscape

Biosimilar introductions are profoundly impacting the competitive dynamics within the global Liposomal Amphotericin B market. Traditionally, a limited number of innovator products dominated, enjoying substantial market share and pricing power due to their complex manufacturing and regulatory hurdles. However, the emergence of biosimilar versions, offering comparable safety and efficacy at significantly lower costs, is disrupting this established order. These new entrants are intensifying price competition, forcing innovator companies to reevaluate their pricing strategies and potentially offer discounts to retain market share. Furthermore, the availability of more affordable alternatives is expanding patient access, particularly in regions where the high cost of innovator drugs was a barrier. This increased accessibility and competitive pricing pressure are leading to a shift in prescription patterns, reshaping the market landscape by introducing more players and fostering a more competitive environment.

What are the Key Drivers Shaping the Global Liposomal Amphotericin B Market

Rising Incidence of Fungal Infections and Associated Mortality

The increasing prevalence of fungal infections globally, particularly among immunocompromised individuals, is a primary driver for the liposomal amphotericin B market. Conditions such as organ transplantation, HIV AIDS, cancer chemotherapy, and extensive use of corticosteroids significantly weaken the immune system, making patients highly susceptible to severe and invasive fungal diseases like aspergillosis, candidiasis, and cryptococcosis. These infections are often life threatening and associated with high mortality rates if not treated effectively. Liposomal amphotericin B offers a crucial advantage in these scenarios due to its improved safety profile, reduced nephrotoxicity, and enhanced drug delivery to infection sites compared to conventional amphotericin B formulations. This makes it the preferred treatment option for severe and refractory fungal infections, thereby fueling its demand.

Superior Efficacy and Reduced Toxicity Profile of Liposomal Amphotericin B

Liposomal Amphotericin B offers a significant advantage over conventional amphotericin B due to its superior efficacy and reduced toxicity profile. Traditional amphotericin B is known for its severe side effects, including nephrotoxicity and infusion related reactions, which often limit its use. The liposomal formulation encapsulates the drug within lipid vesicles, leading to targeted delivery to fungal infection sites while minimizing exposure to healthy host cells. This targeted delivery enhances the drug's effectiveness against a broad spectrum of fungal pathogens. The reduced toxicity translates into improved patient tolerability, allowing for higher dosages and longer treatment durations when necessary. This crucial benefit drives its increased adoption in treating serious fungal infections.

Increasing R&D Investments and Product Innovation in Antifungal Therapies

Increasing research and development investments are a crucial driver in the Global Liposomal Amphotericin B Market. Pharmaceutical and biotechnology companies are channeling significant resources into discovering and developing novel antifungal therapies. This surge in investment is fueled by the growing burden of invasive fungal infections and the persistent challenge of antifungal resistance. Companies are actively exploring new formulations, drug delivery systems, and combination therapies to improve efficacy, reduce toxicity, and broaden the spectrum of activity for existing antifungal agents like liposomal amphotericin B. This innovation push aims to address unmet clinical needs, enhance patient outcomes, and expand the therapeutic applications of advanced antifungal solutions. The focus on product innovation ensures a steady pipeline of improved treatments, thereby propelling market expansion.

Global Liposomal Amphotericin B Market Restraints

Stringent Regulatory Hurdles for New Entrants

New companies entering the global liposomal amphotericin B market face significant challenges due to stringent regulatory hurdles. Developing and commercializing these complex lipid-encapsulated formulations demands extensive preclinical and clinical trials. Regulatory bodies like the FDA and EMA require comprehensive data demonstrating safety, efficacy, and consistent product quality. This includes detailed information on manufacturing processes, quality control, stability, and bioavailability. Achieving regulatory approval is a lengthy, costly, and resource-intensive endeavor, often requiring years of research and development. The need to comply with Good Manufacturing Practices GMP and stringent analytical testing adds further complexity and expense. These rigorous requirements create high barriers to entry, favoring established pharmaceutical companies with substantial financial resources and expertise in navigating complex regulatory pathways, thereby limiting competition from new players.

High Cost of Liposomal Amphotericin B Limiting Accessibility

The high cost of liposomal amphotericin B significantly restricts its global availability, especially in low and middle income countries. This financial barrier prevents widespread use, despite the drug being a crucial treatment for life threatening fungal infections. Many healthcare systems struggle to afford the medication, leading to limited stock and preferential allocation to critical cases. Patients in resource constrained settings often cannot access this essential medicine, contributing to higher morbidity and mortality from fungal diseases. The drug's premium pricing limits its adoption in public health programs and makes it unaffordable for individual patients without comprehensive insurance. This economic hurdle thus constrains the overall market growth and equitable distribution of liposomal amphotericin B worldwide.

Global Liposomal Amphotericin B Market Opportunities

Expanding Liposomal Amphotericin B Adoption in Emerging Markets and Underserved Regions

Liposomal Amphotericin B offers a safer, more effective treatment for severe fungal infections compared to conventional amphotericin B, which carries significant toxicity risks. Expanding its adoption in emerging markets and underserved regions presents a critical opportunity to address a substantial unmet medical need. These areas often experience a high burden of life threatening fungal diseases like cryptococcal meningitis and aspergillosis, exacerbated by immunocompromised populations and limited diagnostic capabilities.

The opportunity lies in overcoming existing barriers such as high costs, lack of awareness, and inadequate healthcare infrastructure. Strategic initiatives focusing on tiered pricing models, educational programs for healthcare professionals, and collaborations with local governments and NGOs can significantly improve access. By making this superior antifungal therapy more available and affordable, companies can not only improve patient outcomes and save lives but also tap into a vast, growing market segment. This expansion aligns with global health equity goals, fostering market growth through humanitarian impact.

Unlocking Prophylactic and Early Intervention Applications for Liposomal Amphotericin B in High-Risk Groups

This opportunity focuses on strategically expanding Liposomal Amphotericin B's utility beyond its current role as a rescue therapy for established invasive fungal infections. The core potential lies in proactively deploying LAmB in high-risk groups, including severely immunocompromised cancer patients undergoing chemotherapy, organ transplant recipients, and critically ill individuals with compromised immune systems. Implementing prophylactic regimens can prevent life threatening fungal infections before they even emerge, significantly improving patient safety and reducing healthcare burdens. Similarly, early intervention strategies involve administering LAmB at the earliest suspicion of infection in these vulnerable populations. This approach can effectively halt disease progression, mitigate severe complications, and enhance overall survival rates, shifting the paradigm from reactive treatment to proactive disease management. This expansion offers substantial benefits by optimizing patient outcomes, reducing the need for intensive care, and potentially shortening hospitalizations, especially as healthcare access grows globally.

Global Liposomal Amphotericin B Market Segmentation Analysis

Key Market Segments

By Dosage Strength

  • •2 mg/vial
  • •10 mg/vial
  • •50 mg/vial

By Form

  • •Lyophilized Powder for Injection
  • •Lipid Suspension

By Indication

  • •Invasive Fungal Infections
  • •Cryptococcal Meningitis
  • •Aspergillosis
  • •Candidiasis
  • •Visceral Leishmaniasis
  • •Others

By End User

  • •Hospitals
  • •Specialty Clinics
  • •Ambulatory Surgical Centers
  • •Research Institutes

Segment Share By Dosage Strength

Share, By Dosage Strength, 2025 (%)

  • 2 mg/vial
  • 10 mg/vial
  • 50 mg/vial
maklogo
$1.25BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why is the 50 mg/vial dosage strength dominating the Global Liposomal Amphotericin B Market?

This dosage strength holds a significant majority share due to its widespread adoption in treating severe and systemic fungal infections. Hospitals and specialty clinics frequently utilize the 50 mg/vial presentation for adult patients requiring intensive therapy, offering a convenient and effective solution for managing critical conditions where higher doses are often necessary. Its cost effectiveness per dose and established efficacy across various indications contribute significantly to its market leadership.

Which indication drives the majority demand for Liposomal Amphotericin B?

Invasive Fungal Infections are the leading indication, encompassing a broad spectrum of life threatening conditions including Aspergillosis, Cryptococcal Meningitis, and severe Candidiasis. These infections often affect immunocompromised patients, necessitating potent antifungal agents. Liposomal Amphotericin B is a crucial first line or salvage therapy due to its broad spectrum activity and improved safety profile compared to conventional Amphotericin B, making it indispensable for these critical indications.

How do end user segments contribute to the market dynamics?

Hospitals represent the largest end user segment, accounting for a substantial portion of the market due to their capacity for managing severe and complicated fungal infections, including those requiring intensive care. Their infrastructure, specialized staff, and ability to handle inpatient admissions for prolonged treatments make them the primary point of care. Specialty clinics also contribute significantly, particularly for outpatient management or follow up care, while research institutes drive innovation and new applications.

Global Liposomal Amphotericin B Market Regulatory and Policy Environment Analysis

The global Liposomal Amphotericin B market navigates a complex mosaic of regulatory and policy environments. Key pharmaceutical authorities such as the US Food and Drug Administration, European Medicines Agency, and their counterparts in Japan, China, and India impose rigorous requirements for drug approval. These include stringent clinical trial evidence, robust manufacturing quality standards adherence to Good Manufacturing Practices, and comprehensive post market surveillance. Pricing and reimbursement policies exhibit significant regional variations, influenced by national healthcare systems, formulary listings, and government procurement strategies. Orphan drug designations or priority review pathways often accelerate market access for specific indications. Intellectual property protection, data exclusivity, and evolving guidelines for complex generics also profoundly shape market dynamics, fostering innovation while balancing affordability and availability across diverse healthcare landscapes.

Which Emerging Technologies Are Driving New Trends in the Market?

Innovations in the Global Liposomal Amphotericin B market are primarily driven by efforts to enhance efficacy and mitigate toxicity. Emerging technologies focus on developing advanced drug delivery systems that improve drug targeting to fungal infection sites, further reducing renal adverse effects and infusion related reactions. Researchers are exploring novel lipid compositions and nanocarrier modifications to achieve more stable formulations with prolonged circulation times.

Significant advancements include the potential for sustained release formulations, minimizing dosing frequency and improving patient compliance, particularly for chronic or recurrent infections. Manufacturing process innovations aim to reduce production costs, making this vital antifungal therapy more accessible globally. Future developments may also involve personalized medicine approaches, utilizing pharmacogenomics to optimize dosing and minimize side effects for individual patients. The integration of artificial intelligence in drug discovery and formulation development promises to accelerate the introduction of next generation liposomal amphotericin B products with superior therapeutic profiles. These ongoing innovations are poised to reshape treatment paradigms for severe fungal infections.

Global Liposomal Amphotericin B Market Regional Analysis

Global Liposomal Amphotericin B Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
38.2%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

Dominant Region

North America · 38.2% share

North America emerged as the dominant region in the Global Liposomal Amphotericin B Market, securing a significant 38.2% market share. This leadership is primarily attributed to several key factors. The region benefits from a robust healthcare infrastructure, characterized by advanced medical facilities and widespread access to specialized treatments. High healthcare expenditure per capita in countries like the United States and Canada fuels demand for innovative and effective antifungal therapies. Furthermore, the presence of major pharmaceutical companies and active research and development initiatives in North America contributes to product innovation and market penetration. A high prevalence of fungal infections, particularly among immunocompromised patients, also drives the adoption of liposomal amphotericin B. Favorable reimbursement policies further support the market's growth and accessibility in this region.

Fastest Growing Region

Asia Pacific · 9.2% CAGR

The Asia Pacific region is poised to be the fastest growing region in theosomal Amphotericin B Market from 2026 to 2035, exhibiting a robust Compound Annual Growth Rate of 9.2%. This impressive growth is fueled by several key factors. A burgeoning patient population coupled with increasing awareness of invasive fungal infections contributes significantly. Furthermore, improving healthcare infrastructure and expanding access to advanced medical treatments in countries like China and India are propelling market expansion. Rising disposable incomes and a growing demand for effective antifungal therapies are also crucial drivers. The region's proactive approach towards healthcare innovation and a strong focus on improving patient outcomes further solidify its position as a leading growth engine.

Impact of Geopolitical and Macroeconomic Factors

Geopolitical stability and access to raw materials for liposomal formulations significantly impact the supply chain for amphotericin B. Trade policies, particularly those affecting pharmaceutical ingredient imports from countries like China and India, can create price volatility and availability challenges. Furthermore, intellectual property rights and patent enforcement in various regions influence market competition and the entry of generic liposomal amphotericin B versions. Geopolitical tensions may disrupt manufacturing and distribution networks, affecting overall market supply and pricing.

Macroeconomic factors, including healthcare expenditure trends and government healthcare policies, profoundly influence demand. Economic recessions can lead to budget constraints for public health systems, potentially impacting procurement of premium drugs like liposomal amphotericin B. Exchange rate fluctuations affect the profitability of multinational pharmaceutical companies and the affordability of the drug in different markets. Inflationary pressures on manufacturing costs, R&D investments, and distribution expenses can also drive up final product pricing. Healthcare insurance coverage and reimbursement policies are crucial determinants of patient access and market growth.

Recent Developments

  • March 2025

    Glenmark Pharmaceuticals Ltd. announced the launch of a new, more affordable generic version of Liposomal Amphotericin B in several developing markets. This strategic initiative aims to expand access to critical antifungal treatment by offering a cost-effective alternative to existing brands.

  • May 2025

    Gilead Sciences Inc. and Astellas Pharma Inc. entered into a strategic partnership to co-develop and co-commercialize an enhanced formulation of Liposomal Amphotericin B. This collaboration seeks to leverage both companies' R&D strengths to improve drug delivery and patient outcomes.

  • July 2024

    United Biotech Pvt. Ltd. successfully secured regulatory approval for its Liposomal Amphotericin B product in a major Southeast Asian market. This product launch marks a significant expansion of their geographical footprint and market penetration in a region with high demand for antifungal agents.

  • September 2024

    Zydus Lifesciences Limited acquired a specialized manufacturing facility from Samarth Life Sciences Pvt. Ltd. focused on liposomal drug production. This acquisition is a strategic move to bolster Zydus's production capabilities and ensure a robust supply chain for its Liposomal Amphotericin B offerings.

Key Players Analysis

Leading players like Gilead Sciences and Astellas Pharma drive the global liposomal amphotericin B market through advanced drug delivery systems. Companies such as Glenmark, Intas, and Zydus contribute significantly with their extensive product portfolios and strategic partnerships, enhancing market penetration. Bharat Serums and Vaccines alongside United Biotech focus on expanding access and manufacturing capabilities. Innovations in liposomal technology and rising demand for effective antifungal treatments are key growth drivers across these industry leaders.

List of Key Companies:

  1. Glenmark Pharmaceuticals Ltd.
  2. Gilead Sciences Inc.
  3. United Biotech Pvt. Ltd.
  4. Bharat Serums and Vaccines Limited
  5. Intas Pharmaceuticals Ltd.
  6. Zydus Lifesciences Limited
  7. Cipla Limited
  8. Astellas Pharma Inc.
  9. Samarth Life Sciences Pvt. Ltd.
  10. Bristol-Myers Squibb Company
  11. Lupin Limited
  12. Sun Pharmaceutical Industries Ltd.

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 1.25 Billion
Forecast Value (2035)USD 2.41 Billion
CAGR (2026-2035)8.2%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Dosage Strength:
    • •2 mg/vial
    • •10 mg/vial
    • •50 mg/vial
  • By Form:
    • •Lyophilized Powder for Injection
    • •Lipid Suspension
  • By Indication:
    • •Invasive Fungal Infections
    • •Cryptococcal Meningitis
    • •Aspergillosis
    • •Candidiasis
    • •Visceral Leishmaniasis
    • •Others
  • By End User:
    • •Hospitals
    • •Specialty Clinics
    • •Ambulatory Surgical Centers
    • •Research Institutes
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Liposomal Amphotericin B Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Dosage Strength
5.1.1. 2 mg/vial
5.1.2. 10 mg/vial
5.1.3. 50 mg/vial
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Form
5.2.1. Lyophilized Powder for Injection
5.2.2. Lipid Suspension
5.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
5.3.1. Invasive Fungal Infections
5.3.2. Cryptococcal Meningitis
5.3.3. Aspergillosis
5.3.4. Candidiasis
5.3.5. Visceral Leishmaniasis
5.3.6. Others
5.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
5.4.1. Hospitals
5.4.2. Specialty Clinics
5.4.3. Ambulatory Surgical Centers
5.4.4. Research Institutes
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Liposomal Amphotericin B Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Dosage Strength
6.1.1. 2 mg/vial
6.1.2. 10 mg/vial
6.1.3. 50 mg/vial
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Form
6.2.1. Lyophilized Powder for Injection
6.2.2. Lipid Suspension
6.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
6.3.1. Invasive Fungal Infections
6.3.2. Cryptococcal Meningitis
6.3.3. Aspergillosis
6.3.4. Candidiasis
6.3.5. Visceral Leishmaniasis
6.3.6. Others
6.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
6.4.1. Hospitals
6.4.2. Specialty Clinics
6.4.3. Ambulatory Surgical Centers
6.4.4. Research Institutes
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe Liposomal Amphotericin B Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Dosage Strength
7.1.1. 2 mg/vial
7.1.2. 10 mg/vial
7.1.3. 50 mg/vial
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Form
7.2.1. Lyophilized Powder for Injection
7.2.2. Lipid Suspension
7.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
7.3.1. Invasive Fungal Infections
7.3.2. Cryptococcal Meningitis
7.3.3. Aspergillosis
7.3.4. Candidiasis
7.3.5. Visceral Leishmaniasis
7.3.6. Others
7.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
7.4.1. Hospitals
7.4.2. Specialty Clinics
7.4.3. Ambulatory Surgical Centers
7.4.4. Research Institutes
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific Liposomal Amphotericin B Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Dosage Strength
8.1.1. 2 mg/vial
8.1.2. 10 mg/vial
8.1.3. 50 mg/vial
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Form
8.2.1. Lyophilized Powder for Injection
8.2.2. Lipid Suspension
8.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
8.3.1. Invasive Fungal Infections
8.3.2. Cryptococcal Meningitis
8.3.3. Aspergillosis
8.3.4. Candidiasis
8.3.5. Visceral Leishmaniasis
8.3.6. Others
8.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
8.4.1. Hospitals
8.4.2. Specialty Clinics
8.4.3. Ambulatory Surgical Centers
8.4.4. Research Institutes
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America Liposomal Amphotericin B Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Dosage Strength
9.1.1. 2 mg/vial
9.1.2. 10 mg/vial
9.1.3. 50 mg/vial
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Form
9.2.1. Lyophilized Powder for Injection
9.2.2. Lipid Suspension
9.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
9.3.1. Invasive Fungal Infections
9.3.2. Cryptococcal Meningitis
9.3.3. Aspergillosis
9.3.4. Candidiasis
9.3.5. Visceral Leishmaniasis
9.3.6. Others
9.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.4.3. Ambulatory Surgical Centers
9.4.4. Research Institutes
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa Liposomal Amphotericin B Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Dosage Strength
10.1.1. 2 mg/vial
10.1.2. 10 mg/vial
10.1.3. 50 mg/vial
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Form
10.2.1. Lyophilized Powder for Injection
10.2.2. Lipid Suspension
10.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
10.3.1. Invasive Fungal Infections
10.3.2. Cryptococcal Meningitis
10.3.3. Aspergillosis
10.3.4. Candidiasis
10.3.5. Visceral Leishmaniasis
10.3.6. Others
10.4. Market Analysis, Insights and Forecast, 2020-2035, By End User
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Ambulatory Surgical Centers
10.4.4. Research Institutes
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Glenmark Pharmaceuticals Ltd.
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Gilead Sciences Inc.
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. United Biotech Pvt. Ltd.
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Bharat Serums and Vaccines Limited
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Intas Pharmaceuticals Ltd.
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Zydus Lifesciences Limited
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Cipla Limited
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Astellas Pharma Inc.
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. Samarth Life Sciences Pvt. Ltd.
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. Bristol-Myers Squibb Company
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. Lupin Limited
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Sun Pharmaceutical Industries Ltd.
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Dosage Strength, 2020-2035

Table 2: Global Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Form, 2020-2035

Table 3: Global Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 4: Global Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 5: Global Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Dosage Strength, 2020-2035

Table 7: North America Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Form, 2020-2035

Table 8: North America Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 9: North America Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 10: North America Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Dosage Strength, 2020-2035

Table 12: Europe Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Form, 2020-2035

Table 13: Europe Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 14: Europe Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 15: Europe Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Dosage Strength, 2020-2035

Table 17: Asia Pacific Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Form, 2020-2035

Table 18: Asia Pacific Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 19: Asia Pacific Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 20: Asia Pacific Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Dosage Strength, 2020-2035

Table 22: Latin America Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Form, 2020-2035

Table 23: Latin America Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 24: Latin America Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 25: Latin America Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Dosage Strength, 2020-2035

Table 27: Middle East & Africa Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Form, 2020-2035

Table 28: Middle East & Africa Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 29: Middle East & Africa Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 30: Middle East & Africa Liposomal Amphotericin B Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Healthcare Market Research

Explore comprehensive market research reports covering all aspects of the Healthcare industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;